Authors: Michal Vrablík 1; Jan Piťha 2,3; Vladimír Bláha 4; Renata Cífková 5; Tomáš Freiberger 6; David Karásek 7; Pavel Kraml 8; Hana Rosolová 9; Vladimír Soška 10; Tomáš Štulc 1; Zuzana Urbanová 11 Authors‘ workplace: III. interní klinika 1. LF UK a VFN v Praze 1; Interní klinika 2. LF UK a FN Motol, Praha 2; Centrum experimentální medicíny IKEM, Praha 3; III. interní gerontometabolická klinika LF UK a FN Hradec Králové 4; Centrum kardiovaskulární prevence 1. LF UK a Thomayerova nemocnice, Praha 5; Centrum kardiovaskulární a transplantační chirurgie, Brno 6; III. interní klinika – nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc 7; II. interní klinika 3. LF UK a FN Královské Vinohrady, Praha 8; II. interní klinika LF UK a FN Plzeň 9; Oddělení klinické biochemie ICRC a II. interní klinika LF MU FN u sv. Anny v Brně 10; Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze 11 Published in: AtheroRev 2019; 4(1): 7-18 Category: Guidelines
In recent years there has been an increasing interest in the use of nutraceuticals to improve the treatment of dyslipidemia. According to the results of relevant studies, nutraceuticals can contribute to achieving the target lipid levels and thereby to further reducing of cardiovascular risk. Some nutraceuticals have significant hypolipidemic effects confirmed in studies, some of which can also positively influence other cardiovascular risk factors such as endothelial function and vascular wall compliance. The clinical experience with nutraceuticals administered alone or in combination has been far from unequivocal, and our data for many nutraceuticals are very limited and questionable. The aim of this statement is to provide an overview of nutraceuticals with regard to influencing dyslipidemia in patients not yet taking statins, patients taking statins or combination therapy who have not reached the target lipid levels, and in those with statin intolerance. This statement is intended for doctors and other healthcare professionals involved in the diagnosis and treatment of patients with lipid metabolism disorders, especially in primary prevention. The text is based on the consensus of the International Lipid Expert Panel (ILEP), and was published in 2017 in the journal Nutritional Research [1]. We refer to this publication in the detail section and, for the sake of clarity, we retain selected references to the literature in the original numbering of the original article (citations are available in the electronic version of the journal at www.atheroreview.eu).
combination therapy – dyslipidemia – hypolipidemic drugs – nutraceuticals
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
